Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
Net Issuance of Debt
Ondine Biomedical Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Net Issuance of Debt
CA$4.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Titan Medical Inc
TSX:TMD
|
Net Issuance of Debt
-$580k
|
CAGR 3-Years
-317%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Profound Medical Corp
TSX:PRN
|
Net Issuance of Debt
-$2.6m
|
CAGR 3-Years
-88%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
![]() |
Nanalysis Scientific Corp
XTSX:NSCI
|
Net Issuance of Debt
CA$10.7m
|
CAGR 3-Years
118%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
![]() |
Theralase Technologies Inc
XTSX:TLT
|
Net Issuance of Debt
-CA$117.2k
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-15%
|
|
![]() |
MedMira Inc
XTSX:MIR
|
Net Issuance of Debt
CA$537.5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Net Issuance of Debt?
Net Issuance of Debt
4.5m
CAD
Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Net Issuance of Debt amounts to 4.5m CAD.